Annie McGuire
Human Resources Officer at VERACYTE, INC.
Net worth: 2 M $ as of 31/05/2024
Annie McGuire active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VERACYTE, INC. | Human Resources Officer | - | - |
| General Counsel | 28/02/2022 | - |
Career history of Annie McGuire
Former positions of Annie McGuire
| Companies | Position | Start | End |
|---|---|---|---|
| MYOKARDIA, INC. | Corporate Officer/Principal | - | - |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Rakuten Medical, Inc.
 Rakuten Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Rakuten Medical, Inc. operates as a clinical stage biotechnology company which develops tumor-targeted precision therapies. It develops new anticancer therapies based on the photoimmunotherapy platform. The company was founded in 2010 and is headquartered in San Diego, CA. | General Counsel | - | - |
| Corporate Secretary | - | - |
Training of Annie McGuire
| New York Law School | Graduate Degree |
| Pace University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| General Counsel | 2 |
| Corporate Officer/Principal | 2 |
| Human Resources Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| VERACYTE, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Rakuten Medical, Inc.
Rakuten Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Rakuten Medical, Inc. operates as a clinical stage biotechnology company which develops tumor-targeted precision therapies. It develops new anticancer therapies based on the photoimmunotherapy platform. The company was founded in 2010 and is headquartered in San Diego, CA. | Commercial Services |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Annie McGuire
- Experience
